Merck & Co Inc, which has largely kept to the sidelines of the race for COVID-19 treatments, said it was buying Austrian vaccine maker Themis Bioscience and would collaborate with research nonprofit IAVI to develop two separate vaccines. It also announced a partnership with privately held Ridgeback Biotherapeutics to develop an experimental oral antiviral drug against COVID-19, the respiratory disease caused by the novel coronavirus. It did not disclose the terms of the acquisition of Themis, a privately held company.
from Yahoo Finance https://ift.tt/3d8O6hG
Leave a Reply